Infliximab Is Not Associated With Increased Risk of Malignancy or Hemophagocytic Lymphohistiocytosis in Pediatric Patients With Inflammatory Bowel Disease.
Hyams JS, Dubinsky MC, Baldassano RN, Colletti RB, Cucchiara S, Escher J, Faubion W, Fell J, Gold BD, Griffiths A, Koletzko S, Kugathasan S, Markowitz J, Ruemmele FM, Veereman G, Winter H, Masel N, Shin CR, Tang KL, Thayu M.
Hyams JS, et al.
Gastroenterology. 2017 Jun;152(8):1901-1914.e3. doi: 10.1053/j.gastro.2017.02.004. Epub 2017 Feb 11.
Gastroenterology. 2017.
PMID: 28193515